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1071-9091/11ders. Currently mutations in at least 27 different genes have been reported to cause a congenital
myopathy, but the number is expected to increase due to the accelerated use of next-generation
sequencing methods. There is substantial overlap between the causative genes and the clinical
and histopathologic features of the congenital myopathies. The mode of inheritance can be auto-
somal recessive, autosomal dominant or X-linked. Both dominant and recessive mutations in the
same gene can cause a similar disease phenotype, and the same clinical phenotype can also be
caused by mutations in different genes. Clear genotype-phenotype correlations are few and far
between.
Semin Pediatr Neurol 29:12-22 © 2019 Elsevier Inc. All rights reserved.Introduction
The application of next-generation sequencing methods,such as whole-exome sequencing, targeted gene panels,
and whole-genome sequencing has resulted in an accelerated
discovery of novel disease genes and disease-causing variants
underlying the various types of congenital myopathies. Further-
more, the use of custom high-density oligonucleotide arrays for
comparative genomic hybridization has enabled the discovery
of large copy number variations (CNVs) causing, for example,
nemaline myopathy and centronuclear myopathy.13
The inheritance of congenital myopathies can be autosomal
dominant, autosomal recessive or X-linked. De novo domi-
nant disease-causing variants are common in some genes, for
example, ACTA1 and TPM2.4,5 Both dominant and recessive
variants have been described in several genes, for example,
ACTA1, TPM2, TPM3, RYR1, MYH2, and TTN.48 Interest-
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myopathy. This has been described for RYR1 and core myopa-
thies.9 Furthermore, it has been suggested that a common
pathophysiological pathway caused by epigenetic changes is
activated in some forms of congenital myopathies.10
Mutations in the same gene can result in more than 1 clini-
cal phenotype, and the same clinical phenotype can result
from mutations in several different genes.11 There is also sub-
stantial variation in the severity of the clinical phenotype,
even within 1 genetic entity, seldom with any discernible
genotype-phenotype correlations.12Nemaline Myopathies Including
CapMyopathy and Fiber-Type
Disproportion
The clinical spectrum of nemaline myopathies (NM) is wide,
ranging from severe congenital forms, sometimes already detect-
able in utero, through the typical form to milder childhood-
onset and even adult-onset forms. Nemaline rods, derived from
sarcomeric Z discs, and often type 1 fiber predominance, are
characteristic pathological features of NM. Cap myopathy is
pathologically characterised by cap-like structures of disorgan-
ised myofibrils and thickened Z discs, but usually no large
rods.11 Following the description of families and patients with
variable presence of nemaline rods and/or caps,13,14 NM and
cap myopathy are considered to be overlapping entities. Fiber-
type disproportion (FTD), that is, type 1 hypotrophy in the
Congenital Myopathy Genetics 13presence of larger type 2 fibers, but in the absence of specific
pathological features, may be caused by the same genes as NM
and cap myopathy.11 FTD and type 1 fiber predominance are
common features in the other congenital myopathies also,
caused by mutations in other genes.
Eleven NM-causing genes have been described to date1525
(Fig., Table). Seven of these genes, that is, ACTA1, NEB, TPM2,
TPM3, TNNT1, LMOD3, and MYPN, encode structural proteins
of the skeletal muscle sarcomere, CFL2 regulates actin filament
dynamics and is essential for muscle maintenance, whereas
three of the genes, that is, KBTBD13, KLHL40, and KLHL41,
encode proteins involved in the maintenance of sarcomeric
integrity by regulating turnover of sarcomeric proteins.The Nebulin Gene (NEB)
Disease-causing variants in the nebulin gene (NEB) are the
most common cause of autosomal recessive NM, accounting
for approximately 50% of all NM cases, and the most com-
mon cause of the typical form. The majority of the patients
are compound heterozygous for 2 different NEB mutations.
Point mutations causing aberrant splicing, small indels caus-
ing frameshifts, and nonsense mutations are the most com-
mon mutation types in NEB.12 A custom high-density
oligonucleotide array, the NM-CGH array, has revealed sev-
eral large, 1-143 kb, CNVs in NEB, including recurrent
CNVs in the triplicate region spanning exons 82-105.1,26
Eight exons are repeated 3 times in the 32-kb triplicate (TRI)
region of NEB, and the normal copy number is 6 (3 copies in
each allele). Deletion or duplication of one TRI copy is non-
pathogenic, but gains of 2 or more TRI copies segregate with
NM in 4% of the families studied, and are, thus, interpreted
to be pathogenic. The CNVs in the TRI region of NEB can
currently be detected only using the NM-CGH-array.26 We
have estimated that a large pathogenic CNV in NEB is present
in 10%-15% of NM patients.Figure Congenital myopathy-causing genes. The diagram show
myopathies, and the overlap between different entities. Cor
between nemaline myopathy and core myopathy.Missense variants are very common in NEB. In the current
release of the ExAC Browser (http://exac.broadinstitute.org),
63% of the variants in the coding region (including splice sites
and UTRs) of NEB are missense, 24% are synonymous changes,
and 4% are apparent pathogenic variants (nonsense, splice site,
frameshift, indels). Most of the missense variants are rare, 76%
of the variants being present in only 1-3 heterozygous carriers
(allele frequencies well below 0.01). This makes the interpreta-
tion of the pathogenicity of missense variants extremely difficult.
Our current recommendation is that only variants affecting con-
served actin- and tropomyosin-binding sites in NEB can readily
be considered as pathogenic, but all the others require functional
studies for assessment of their pathogenicity. Actin- and tropo-
myosin-binding experiments may be used for this purpose.27
In addition to the “classical” forms of NM, recessive disease-
causing variants in NEB may cause distal nebulin myopathy
without nemaline rods,28 core-rod myopathy,29 distal forms
of NM,30 and lethal multiple pterygium syndrome.31
To date, only 1 clearly dominant NEB variant has been
found. It is a »100 kb in-frame deletion spanning NEB exons
14-89 resulting in the expression of substantially smaller nebu-
lin proteins, expected to have a dominant-negative effect. This
variant segregates with a distal form of NM in a 3-generation
Finnish family.The Skeletal Muscle Alpha-Actin Gene
(ACTA1)
According to our estimate, 23% of NM cases are caused by
mutations in ACTA1. Most of the pathogenic variants in ACTA1
are dominant (90%) missense variants, most often causing
severe NM. Of the sporadic cases with ACTA1 variants, approxi-
mately 85% have been shown to be caused by de novo mis-
sense variants. Autosomal recessive variants are rarer (10%),
and result in null alleles (splice site, nonsense, frameshift, and
some missense variants).32 Dominant variants inherited acrosss 27 genes implicated in various forms of the congenital
e-rod myopathy was included to illustrate the overlap
Table Genes Causing Congenital Myopathies
Disorder Gene Inheritance Other Entities Caused byMutations in the Gene
Nemaline myopathy NEB AR, AD* Distal nebulin myopathy, distal nemaline myopathy, core-rod
myopathy, lethal multiple pterygium syndrome
ACTA1 de novo, AD, AR Actin-accumulation myopathy, core-rod myopathy, intranuclear
rod myopathy, zebra body myopathy, CFTD, progressive
scapuloperoneal myopathy, distal nemaline myopathy
TPM3 AD, de novo, AR CFTD
TPM2 AD, de novo, AR† CFTD, core-rod myopathy, distal arthrogryposis, Escobar
syndrome (AR)
TNNT1 AR
CFL2 AR
LMOD3 AR
MYPN AR Cardiomyopathy
KBTBD13 AD
KLHL40 AR
KLHL41 AR
Core myopathy RYR1 AD, AR Core-rod myopathy, CFTD, malignant hyperthermia,
multi-minicore disease with ophthalmoplegia, arthrogryposis
multiplex congenita
SEPN1 AR Rigid spine muscular dystrophy, CFTD, desmin-related myopathy
with Mallory body-like inclusions, myofibrillar myopathy
TTN AR TMD, LGMD2J, HMERF, adult-onset recessive proximal mus-
cular dystrophy, Emery-Dreifuss-like phenotype without
cardiomyopathy, cardiomyopathy
MYH7 AD Laing distal myopathy, CFTD, myosin storage myopathy
(hyaline body myopathy), cardiomyopathy
MEGF10 AR
Centronuclear myopathy MTM1 X-linked
DNM2 AD CMTDIB, CMT2M
RYR1 AR See above
BIN1 AR, AD
TTN AR See above
SPEG AR
CCDC78 AD
MYH-related myopathy MYH2 AD, AR
MYH7 AD See above
MYH3 AD Distal arthrogryposis
MYH8 AD Distal arthrogryposis
Other congenital
myopathies
CACNA1S AD, AR Hypokalemic periodic paralysis type 1, malignant hyperthermia
SCN4A AR Hypokalemic periodic paralysis type 2, congenital myasthenic
syndrome 16, myotonia congenita, paramyotonia congenita
ZAK AR Split-foot malformation with mesoaxial polydactyly
AD, autosomal dominant; AR, autosomal recessive; CFTD, congenital fiber type disproportion; CMT, Charcot-Marie-Tooth neuropathy; HMERF,
hereditary myopathy with early respiratory failure; LGMD, limb-girdle muscular dystrophy; TMD, tibial muscular dystrophy.
*Only 1 dominant NEB mutation has been identified to date.
†Only 1 recessive TPM2 mutation has been identified to date.
14 K. Pelin and C. Wallgren-Pettersson2 or more generations have been identified in less than 5% of
ACTA1 families, while mosaicism has been observed in a few
families.32-34 We have recently described a dominant ACTA1
missense variant segregating in a 3-generation family with clini-
cally variable NM, illustrating the clinical and histological vari-
ability of NM between patients sharing the same mutation.
In addition to NM, dominant, mostly de novo, disease-caus-
ing variants in ACTA1 can cause actin-accumulation myopa-
thy,35 cap myopathy,36 congenital fiber type disproportion,37
core-rod myopathy,38 intranuclear rod myopathy,39,40 zebrabody myopathy,41 progressive scapuloperoneal myopathy,42
and distal myopathy with nemaline rods.43The Alpha- and Beta-Tropomyosin Genes
(TPM3 and TPM2)
Mutations in TPM3 and TPM2 are relatively rare causes of NM,
accounting for less than 10% of the cases. In addition to NM,
mutations in TPM3 and TPM2 can cause cap myopathy, core-
rod myopathy, congenital fiber type disproportion, distal
Congenital Myopathy Genetics 15arthrogryposes, and Escobar syndrome.5 The majority of the
mutations in both TPM3 and TPM2 are dominant missense
variants or in-frame deletions removing one amino acid. A few
recurrent mutations have been described in both genes;
p.Lys7del and p.Glu139del in TPM2, and p.Arg168His,
p.Arg168Cys, and p.Arg168Gly in TPM3. The mutations alter
the conserved coiled-coil structure of the tropomyosins,
resulting in aberrant tropomyosin-actin-binding.5,44
Recessive mutations are more common in TPM3 than in
TPM2. In TPM2 only 1 recessive homozygous nonsense muta-
tion has been described, causing Escobar syndrome associated
with NM.45 In TPM3, a few recessive mutations, including non-
sense, frameshift, and stop-lost mutations have been
described.4649 NMs caused by mutations in TPM2 usually have
milder presentations than NMs caused by mutations in TPM3.5
Recessive disease caused by mutations in these genes appears
mostly to be severe. No clear correlation was found between the
type of mutation and the clinical phenotype. Cap formation in
the muscle biopsy may be seen in disorders caused by mutations
in either gene, and type 1 fiber hypotrophy and predominance is
common in both groups.5 Furthermore, we have identified a
large, 17-21 kb homozygous deletion that removes the promoter
and the first 2 exons of TPM3, causing a severe form of NM.2The Troponin T1 Gene (TNNT1)
The first mutation in TNNT1, a recessive nonsense mutation
causing a severe form of NM with tremor in the first months
of life and contractures in the Old Order Amish, was
described almost 20 years ago.18 Not until recently have a
few other NM-causing mutations in TNNT1 been identified,
all showing recessive inheritance. Compound heterozygosity
for a splice site mutation resulting in skipping of TNNT1
exon 8, and an exon 14 deletion was identified in a Dutch
patient with a similar clinical phenotype as in Amish NM.50
A clinical phenotype similar to Amish NM was also observed
in a Hispanic patient homozygous for a nonsense mutation
(different from the Amish one) in TNNT1.51 Homozygosity
for a complex indel mutation in TNNT1 causing premature
truncation of the protein has been described in 9 unrelated
Palestinian patients with a severe form of NM.52The Cofilin-2 Gene (CFL2)
Recessive mutations in the CFL2 gene are rare causes of NM. The
first CFL2 mutation was described in 2007. The homozygous
missense mutation, p.Ala35Thr, was found to cause NM with
some minicores in a large consanguineous family of Middle East-
ern origin showing congenital onset, delayed milestones and no
facial weakness or foot drop.20 The second CFL2 mutation was
published in 2012. Again a homozygous missense mutation, in
this case p.Val7Met, was found in 2 sisters of Iraqi Kurdish origin
with axial and limb girdle weakness who were born to consan-
guineous parents. The sisters had NM with features of myofibril-
lar myopathy.53 A third mutation described in CFL2 is a
homozygous 4 base pair deletion causing a frameshift,
p.Lys34Glnfs*6. The mutation had caused a severe form of NM
in a Saudi Arabian consanguineous family.54The Leiomodin-3 Gene (LMOD3)
Recessive mutations in LMOD3 have hitherto been described
in 15 families with severe, often lethal forms of NM, which in
some cases were associated with perinatal fractures.24,55 Most
of the mutations are nonsense or frameshift variants causing
loss of leiomodin-3 protein expression. The patients were
homozygous or compound heterozygous for the mutations.24The Myopalladin Gene (MYPN)
Recessive mutations in MYPN have been described in four fami-
lies with childhood or adult-onset mild NM, and in 2 families
with congenital slowly progressive cap myopathy.25,56 AllMYPN
mutations described to date are loss-of-function variants, either
nonsense, frameshift or splice site variants, leading to no or very
low expression of myopalladin in skeletal muscle. The patients
are either homozygous or compound heterozygous for the muta-
tions. Intranuclear rods, previously only associated with ACTA1
mutations, were observed in the muscle biopsies of 2 of the
patients with mild NM.25 Interestingly, dominant MYPN muta-
tions have been reported to cause dilated, familial hypertrophic
or familial restrictive cardiomyopathy.5759 Contrary to the NM-
and cap myopathy-causing mutations, the cardiomyopathy-
causing MYPN mutations lead to the expression of mutant
proteins with dominant-negative effects in cardiomyocytes.58The Kelch Repeat- and BTB/POZ Domain-
Containing Protein 13, the Kelch-Like 40 and
the Kelch-Like 41 Genes (KBTBD13,
KLHL40, and KLHL41)
KBTBD13, KLHL40, and KLHL41 encode proteins of the Kelch
superfamily including altogether 66 genes and 63 protein
members.60 KBTBD13 interacts with Cullin 3 ubiquitin ligase,
and this interaction is required for the formation of a func-
tional Cul3 RING ubiquitin ligase complex, which is involved
in the ubiquitination of proteins destined for degradation.61
Three different missense variants, p.Arg248Ser, p.Lys390Asn,
and p.Arg408Cys in KBTBD13 have been found to cause auto-
somal dominant NM with cores, and unusual clinical presen-
tations including a characteristic slowness of movement.21
KLHL40 has been shown to bind and stabilize nebulin and
LMOD3 in the sarcomere, as well as prevent ubiquitination of
LMOD3.62 Recessive mutations in KLHL40 are a fairly com-
mon cause of severe NM, often with fetal akinesia or hypoki-
nesia and contractures, fractures, respiratory failure, and
swallowing difficulties at birth. Mutations in KLHL40 account
for up to 28% of severe cases of NM in the Japanese popula-
tion due to a founder mutation, p.Glu528Lys.22 One patient
with a mild form of NM has been reported to be homozygous
for a missense mutation, p.Arg500Cys, in KLHL40.63 This
mutation has not been found in the severe cases published to
date.22,64,65 Furthermore, one patient with severe NM due to
compound heterozygous mutations in KLHL40 showed pro-
longed beneficial response to treatment with high-dose acetyl-
cholinesterase inhibitors (pyridostigmine).66 Such a response
16 K. Pelin and C. Wallgren-Petterssonhas also been observed in other congenital myopathies, for
example, myotubular/centronuclear myopathy.67
KLHL41 shows high homology to KLHL40, but KLHL41
preferentially stabilizes nebulin rather than LMOD3.68 Five
families with clinically different forms of NM have been
found to have recessive mutations in KLHL41. Frameshift
mutations correlated with severe phenotypes with neonatal
death, whereas missense variants resulted in impaired motor
function with survival into late childhood and/or early adult-
hood compatible with mild, typical or intermediate NM.23CoreMyopathies
Central core disease, minicore myopathy, and multiminicore
disease are historical definitions of congenital myopathies with
cores, that is, areas devoid of mitochondria and, thus, lack of
oxidative enzyme activity in muscle biopsies. There is patho-
logic, clinical and genetic overlap in congenital myopathies
with cores, and thus the term “core myopathy” is nowadays
preferentially used.11 Five genes have been reported to cause
core myopathies. The ryanodine receptor 1 encoding gene,
RYR1, was the first one to be discovered,69,70 and is now
known as the major core myopathy-causing gene.71 The sec-
ond most common core myopathy-causing gene, SEPN1 enco-
des selenoprotein N.72 Occasional mutations causing core
myopathies have also been described in the satellite cell gene
MEGF10,73 the titin gene TTN,74 and the myosin heavy chain
encoding geneMYH775 (Fig., Table).The Ryanodine Receptor 1 Gene (RYR1)
RYR1 encodes the skeletal muscle specific ryanodine receptor
RYR1, which is a calcium release channel involved in excitation-
contraction coupling activating muscle contraction. Both domi-
nant and recessive mutations in RYR1 have been found to cause
core myopathies, but also related disorders such as core-rod
myopathy, congenital FTD and centronuclear myopathy, as well
as malignant hyperthermia susceptibility.6,76
RYR1 is a large gene with 106 exons encoding a polypeptide
of 5037 amino acids, which forms the subunits of the tetramer
calcium release channel. More than 200 RYR1 mutations have
been reported.77,78 Most mutations causing core myopathies
and malignant hyperthermia are dominant missense variants
changing conserved amino acids, many of them clustered in
specific hotspot regions in the N-terminus, central region and
in the C-terminal transmembrane region of RYR1.71,76 De
novo dominant RYR1 variants have been reported to cause
core-rod myopathy.79-81
Recessive RYR1 mutations are widespread throughout the
gene and patients with such mutations are generally more
severely affected than those with a dominant mutation.82,83
The recessive mutations include null mutations, but also com-
binations of missense variants. Among the recessive variants,
one recurrent allele carrying 3 different missense variants (p.
Ile1571Val, p.Arg3366His, and p.Tyr3933Cys) has been
reported in the Dutch population, but it is unclear whether
one of the variants is causative, or if a combination of 2 or all3 variants cause disease. Furthermore, this 3 missense variant-
carrying allele, as well as some other missense variants are
associated with the malignant hyperthermia trait in heterozy-
gous individuals, but cause recessive RYR1-related myopathies
in homozygous or compound heterozygous individuals.83
In addition to variants affecting a single or a few base pairs,
2 recessive large-scale RYR1 deletions associated with myopa-
thies have been published.84,85 The first one, an in-frame
deletion of 54 out of 106 RYR1 exons, was identified in a
child with a congenital myopathy with lethal neonatal weak-
ness and atypical histopathologic features. The child was
compound heterozygous for the deletion and a single amino
acid duplication.84 The second large deletion starts in RYR1
exon 91 and ends within exon 98, causing a frameshift. The
deletion was detected in a family with recessive late-onset
core myopathy, the patients being compound heterozygous
for the deletion and a missense variant.85 In addition, a reces-
sive deletion of RYR1 exons 70-71 has been described in a
family with severe arthrogryposis multiplex congenita.86
Tissue-specific epigenetic silencing of the maternal RYR1
allele has been documented in a cohort of patients with
recessive core myopathies. Silencing of the maternal allele in
skeletal muscle tissue unmasked the recessive paternal allele
causing the disease.9The Selenoprotein N Gene (SEPN1)
SEPN1 encodes selenoprotein N, which is an integral mem-
brane glycoprotein of the endoplasmic reticulum. SEPN1 is
expressed at high levels in several human fetal tissues, and is
thought to have a role in early muscle development.87
SEPN1 is physically associated with ryanodine receptors and
modifies RYR channel activity.88 Furthermore, it has recently
been shown that SEPN1 is a key component of redox-
regulated calcium metabolism in the endoplasmic reticulum,
through its interaction with the SERCA2 calcium pump.89
Recessive loss-of-function mutations in SEPN1 have
caused entities termed rigid spine muscular dystrophy, core
myopathy, congenital fiber type disproportion, and desmin-
related myopathy with Mallory body-like inclusions.72,90,91
Due to the overlap of clinical and histopathologic features
these disorders are now collectively referred to as SEPN1-
related myopathies. All types of mutations have been identi-
fied in SEPN1, many being truncating nonsense or frameshift
variants, but missense variants affecting conserved amino
acids are also common. Homozygous mutations seem to be
surprisingly prevalent, also in affected children born to non-
consanguineous parents.92,93The Multiple EGF-Like Domain 10 Gene
(MEGF10)
A recessive congenital myopathy with minicores has been
described, caused by missense variants in MEGF10. Three sib-
lings were compound heterozygous for 2 different missense var-
iants, p.Cys326Arg and p.Cys774Arg in MEGF10.73 MEGF10
regulates myoblast function via the NOTCH signalling pathway,
Congenital Myopathy Genetics 17and the interaction between MEGF10 and NOTCH1 is
impaired by the p.Cys774Arg variant.94The Titin Gene (TTN)
The huge TTN gene with 363 exons encodes titin, the largest
polypeptide in nature. One titin molecule reaches from the Z
disc to the M line in the skeletal and cardiac muscle sarco-
meres.95,96 Given the size of titin, it is not surprising that sev-
eral clinically distinct disorders affecting skeletal and/or
cardiac muscle are caused by dominant or recessive muta-
tions in TTN.8 Most of these disorders have adult onset.
However, five patients from 2 families with congenital mus-
cle weakness, minicore-like lesions and abundant centrally
located nuclei, and severe childhood-onset dilated cardiomy-
opathy were found to be homozygous for truncating muta-
tions in the C-terminus of TTN. The parents were
consanguineous in both families.97 Furthermore, in a cohort
of 31 patients with congenital core myopathy combined with
primary heart disease, 7 pathogenic TTN variants were iden-
tified in 5 patients from 4 families. The variants included
missense and truncating mutations. The patients were homo-
zygous or compound heterozygous for the mutations.74The Myosin Heavy Chain 7 Gene (MYH7)
The majority of the more than 500 missense mutations iden-
tified in the slow skeletal muscle fiber myosin heavy chain
encoding gene MYH7 cause cardiomyopathy.98 A subset of
the mutations cause skeletal muscle disease, including Laing
distal myopathy and myosin storage myopathy.99 More
recently mutations in MYH7 have been reported in dominant
core myopathies.75,100 Cullup al. described 4 patients from
2 families affected by multiminicore disease caused by novel
dominant missense mutations in MYH7.75 Romero et al
described four patients in a 3-generation family with autoso-
mal dominant central core disease. They identified a novel
missense mutation in MYH7 that segregated with the disease
in the family.100 The mutations identified in these families
are located in the MYH7 tail region, close to previously
described mutations causing Laing distal myopathy.Centronuclear Myopathies
Centrally located nuclei in the muscle fibers are hallmarks of
centronuclear (myotubular) myopathies (CNM), but some
muscle biopsies may also show additional pathological fea-
tures such as type 1 fiber predominance, type 1 fiber hypo-
trophy, and cores. The most common genes causing
centronuclear myopathies are MTM1, DNM2, RYR1, and
TTN. Minor causative genes are BIN1, CCDC78, and SPEG11
(Fig., Table). RYR1 and TTN variants identified in CNM will
be discussed briefly below. The other CNM genes will be the
focus of separate paragraphs.
Mutations in RYR1 have turned out to be a fairly common
cause of autosomal recessive CNM (ARCNM). The patients
are usually compound heterozygous for 2 mutations, oftenone truncating mutation on one allele and a missense one on
the other allele. The mutations are spread all across the RYR1
gene. Some of the RYR1 mutations found in ARCNM patients
have previously been reported in core myopathy or malig-
nant hyperthermia susceptibility.101104
Compound heterozygous truncating mutations causing
ARCNM have also been identified in the TTN gene. To date,
7 unrelated patients with ARCNM due to mutations in TTN
have been described.103,105,106 The CNM-causing mutations
are spread all along the TTN gene. One of the mutations has
previously been reported to cause tibial muscular dystrophy,
and another caused adult-onset cardiomyopathy in the het-
erozygous state.105The Myotubularin Gene (MTM1)
Mutations in MTM1, encoding myotubularin, a ubiquitously
expressed lipid phosphatase, cause X-linked myotubular
myopathy (XLMTM).107 Myotubularin colocalizes with
RYR1 at the junctional sarcoplasmic reticulum in skeletal
muscle, and it is a key regulator of sarcoplasmic reticulum
remodelling together with its lipid substrate phosphatidyli-
nositol 3-monophosphate (PtdIns3P). Lack of MTM1 activity
leads to disorganisation of the sarcoplasmic reticulum, which
is considered to be the primary cause of most of the organelle
positioning defects observed in muscles biopsies from
XLMTM patients.108
The XLMTM-causing mutations inMTM1 are loss-of-function
mutations spread across the 15 exons of the gene. The majority
of the patients are neonatally severely affected boys. Most muta-
tions are truncating, but missense variants affecting conserved
amino acids essential for MTM1 activity are common also.109,110
A few large deletions removing one or more MTM1 exons, as
well as whole-gene deletions of MTM1 including neighbouring
genes have been reported. The latter causes contiguous gene
syndromes.3,109 Several different types of MTM1 pre-mRNA
splicing affecting mutations have also been described.109,111,112
Germ line mosaicism for de novo MTM1 mutations has been
documented in a few families, in some cases manifesting as
paternal transmission of the X-linked pathogenic variant.109,113
Evidence is accumulating that there is a higher number of
females manifesting XLMTM than previously antici-
pated.3,114 Females with XLMTM are usually less severely
affected than males, but the clinical phenotype is highly vari-
able in age of onset and severity. The most severely affected
females can show a similar clinical course as a severely
affected XLMTM male. In general, those MTM1 mutations
that cause a severe phenotype in males, cause a milder phe-
notype in females, probably due to the normal pattern of
approximately 50-50 X-chromosome inactivation in females.
However, there is an increased prevalence of highly skewed
X-chromosome inactivation in females affected by XLMTM,
although it has not been possible to determine which of the
X chromosomes is preferentially inactivated.114 Not all mani-
festing females show any skew, even in muscle tissue.
Interestingly, dynamin 2 (DNM2) expression levels are
increased in the muscles of XLMTM patients, as well as in
MTM1 knock-out mice, indicating that MTM1 may be a
18 K. Pelin and C. Wallgren-Petterssonnegative regulator of DNM2 expression.115 This finding has
led to the development of a potential therapeutic approach
aiming towards reducing DNM2 levels in the muscles of
XLMTM patients. Proof-of-principle has been achieved with
antisense oligonucleotide-mediated DNM2 knockdown in a
mouse model for XLMTM.116The Dynamin 2 Gene (DNM2)
DNM2 encodes dynamin 2, a large GTPase involved in
diverse cellular processes, among others endocytosis, cytoki-
nesis, phagocytosis, and cell migration. Mutations in DNM2
cause autosomal dominant ADCNM with onset usually in
adolescence or early childhood, with ptosis, distal weakness
and contractures, and often radial strands in muscle fibers
on biopsy, and Charcot-Marie-Tooth (CMT) peripheral neu-
ropathy (CMTDIB and CMT2M).117119 However, cases
with earlier onset have been reported due to de novo muta-
tions in the pleckstrin homology domain of DNM2.120 The
ADCNM-causing mutations in DNM2 are gain-of -function
mutations, predominantly missense variants. One in-frame
deletion of one amino acid, as well as one splice site mutation
causing an in-frame deletion of three amino acids in addition
to an in-frame insertion of 23 new amino acids have been
identified. Many of the missense variants are recurrent and
present in several unrelated families. The mutations causing
ADCNM are distinct from the ones causing CMT.119
Functional studies of common ADCNM DNM2 mutations
show abnormal self-assembly of mutant DNM2 resulting in
abnormally high GTPase activity of the protein, which in
turn leads to T-tubule fragmentation.121 The hyperactive
mutant DNM2 protein is a potential therapeutic target in
ADCNM, that is, downregulation of DNM2 activity should
have a similar beneficial effect in ADCNM muscle as in
XLMTM muscle.116,121The Bridging Integrator 1 Gene (BIN1)
BIN1 encodes for amphiphysin 2, a protein involved in mem-
brane tubulation. The membrane tubulation activity of BIN1
is enhanced by its interaction with MTM1.122 Nicot et al
described the first disease-causing variants in BIN1 10 years
ago. Two missense variants and 1 nonsense variant were
shown to cause ARCNM with congenital or childhood onset
in 3 consanguineous families. The patients were homozygous
for the mutations.123 Subsequently, 1 novel homozygous
missense mutation and 1 novel homozygous nonsense muta-
tion have been published as causative for ARCNM.124,125
Furthermore, a homozygous acceptor splice site mutation in
intron 10 causing abnormal splicing of the skeletal muscle-
specific BIN1 exon 11 was identified in patients with rapidly
progressive ARCNM in 1 consanguineous family. The corre-
sponding splice site was found to be mutated in canine
Inherited Myopathy of Great Danes, which, thus, represents
a mammalian model for BIN1-related CNM.126
Dominant mutations in BIN1 have been reported to cause
mild and adult-onset forms of CNM.127,128 Three of the
mutations are single base pair deletions in the stop codon ofBIN1, causing read-through and extension of the protein
with 52 novel amino acids. Two other dominant mutations
were 1 in-frame deletion of 1 amino acid, and 1 missense
mutation, located in the N-terminus of BIN1.127 A second
dominant missense mutation, also in the N-terminus, was
recently published.128 The dominant BIN1 mutations are dis-
tinct from the recessive ones, with different impacts on pro-
tein function, suggesting different pathomechanisms for
dominant and recessive BIN1-related CNM.127The SPEG Complex Locus Gene (SPEG)
SPEG interacts with myotubularin at the junctional sarcoplas-
mic reticulum in skeletal muscle. SPEG is also expressed in car-
diac muscle. The first SPEG mutations were described in
6 CNM patients from 3 families. In addition to CNM, 2 unre-
lated patients had dilated cardiomyopathy. The mutations were
recessive loss-of-function mutations (nonsense or frameshifts),
and the patients were compound heterozygous or homozygous
for the mutations.129 Two novel SPEG mutations were recently
reported in 2 unrelated CNM patients. One of the patients had
dilated cardiomyopathy also. The patient with CNM and car-
diomyopathy was homozygous for a nonsense mutation, and
the patient with CNM without cardiac involvement was homo-
zygous for a frameshift mutation in SPEG.130The Coiled-Coil Domain-Containing Protein
78 Gene (CCDC78)
Only 1 dominant mutation in CCDC78 causing CNM with
atypical cores has been described in 1 family with patients in
3 generations. The mutation changes the acceptor splice site
of intron 1 in CCDC78, causing retention of the intron,
which is in-frame with the coding sequence. This is predicted
to result in the addition of 74 amino acids to the protein.131Myosin-Related Myopathies
Myosin heavy-chain genes, especially MYH7, MYH2, MYH3,
andMYH8 are implicated in various myopathies affecting skel-
etal and/or cardiac muscle (Fig., Table). Some of these myopa-
thies are congenital. MYH7 was already discussed in the
context of the core myopathies, but dominant mutations in
MYH7 can also cause, for example, congenital fiber type dis-
proportion without any other specific histological features.
One such case was recently reported to be due to a de novo
heterozygous splice site mutation causing skipping of MYH7
exon 38.132 A few cases ofMYH7-related congenital myopathy
were also found in a cohort of Italian patients. These patients
had dominant missense mutations inMYH7.133
Both dominant and recessive mutations in MYH2 can
cause a usually mild congenital myopathy with external oph-
thalmoplegia. The dominant cases are caused by missense
mutations, and the recessive ones usually by truncating
mutations in MYH2.7 A homozygous splice site mutation
causing skipping of MYH2 exon 12, leading to a frameshift,
Congenital Myopathy Genetics 19was recently reported in a consanguineous family where
4 patients had a congenital myopathy with ophthalmople-
gia.134 A novel homozygous frameshift mutation in MYH2
has also recently been described to cause a congenital myop-
athy with chronic aspiration pneumonia in infancy.135
MYH3 and MYH8 encode embryonic and fetal myosin
heavy-chain isoforms. Dominant missense mutations in
MYH3 and MYH8 cause distal arthrogryposis syndromes,
probably as the result of a severe muscle weakness already
during fetal development.7,136,137Other Genes Causing Congenital
Myopathies
Two genes, CACNA1S and SCN4A, previously known
channelopathy-causing genes, have now been implicate in
congenital myopathies as well.138141 A third gene, ZAK,
has also recently been identified as a novel congenital
myopathy-causing gene142 (Fig., Table).
A dihydropyridine receptor (DHPR) congenital myopathy
caused by dominant or recessive mutations in the CACNA1S
gene was recently described in 11 patients from 7 families.
The muscle biopsies showed features of centralised nuclei,
focal zones of sarcomeric disorganisation, and cores. DHPR
directly regulates the RYR1 calcium release channel. Both the
dominant and recessive mutations identified in CACNA1S
are hypothesised to cause a decrease in overall DHPR func-
tion in skeletal muscle.138
Recessive loss-of-function mutations in the SCN4A gene
encoding the alpha-subunit of the skeletal muscle voltage-gated
sodium channel (Nav1.4) have been identified in patients from
8 families with a congenital myopathy of variable severity, severe
or “classical.” Histological features were unspecific; abnormal
fiber size variability, in some with type 1 predominance, and no
pathognomic findings.139141 Partial loss-of-function mutations
were associated with a milder disease phenotype.140
A congenital myopathy with fiber type disproportion
caused by recessive loss-of-function mutations in the mito-
gen-activated protein triple kinase encoding gene, ZAK, was
recently reported in six patients from three families. The
patients were homozygous for frameshift or nonsense muta-
tions in ZAK. The parents were consanguineous in all fami-
lies. All mutations are located in the kinase domain of
ZAK.142 Interestingly, in 2 families recessive mutations in the
SAM domain of ZAK have been associated with split-foot
malformation with mesoaxial polydactyly.143Conclusions
Here we have described 27 different genes implicated in various
forms of the congenital myopathies. It is clear that the number
of genes will increase due to the accelerated use of next-genera-
tion sequencing methods. Moreover, large CNVs and rearrange-
ments are likely to be discovered as causative mutation types in
many more disorders than those currently known.References
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